New registry aims to sharpen TIPS patient selection for liver cirrhosis
NCT ID NCT04801290
First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This registry follows 250 patients with decompensated liver cirrhosis who receive a TIPS procedure, a shunt placed in the liver to reduce pressure. Researchers will track survival, brain function, nutrition, and quality of life over one year. The goal is to identify which patients benefit most and to minimize complications like confusion.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Transjugular intrahepatic portosystemic shunt (TIPS) procedure
- What this could lead to
- If successful, this registry could help doctors better select which patients with liver cirrhosis benefit most from TIPS, improving survival and quality of life while reducing side effects like confusion.
- What could go wrong
- This is an observational registry, not a controlled trial, so it cannot prove cause and effect. Results may not apply to all hospitals or patients. TIPS itself carries risks like worsening confusion or liver function.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DECOMPENSATED LIVER CIRRHOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hannover Medical School
RECRUITINGHanover, Lower Saxony, 30625, Germany
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could growth factors help repair the liver in cirrhosis?
- Could a common cholesterol drug help slow liver failure?
- New blood test could cut unnecessary transfusions in liver patients
- Liver study tracks antibiotic levels in Fluid-Filled bellies
- Shunt surgery may reverse liver failure in some cirrhosis patients
- Engineered immune cells aim to calm liver scarring in first human trial